If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

February 13, 2017 | A version of this story appeared in Volume 95, Issue 7

Frutarom Industries has purchased the shares it did not already own in the savory flavors maker Protein Technologies Ingredients for $40 million. It paid $50 million for a majority stake in 2013.

Oxis Energy, a Cambridge, England, developer of lithium-sulfur battery materials, says it will develop battery cells for a high-altitude “pseudo satellite” to provide remote sensing and internet connectivity in the developing world. Oxis aims to develop a battery cell that will enable the pseudo satellite to fly above the weather for up to three months.

Evonik Industries has invested an undisclosed amount in Hosen Capital Fund III, a Chinese private equity fund that invests in companies in the agriculture and nutrition sector. Evonik has budgeted $105 million to invest in start-ups and venture capital funds.

Teva Pharmaceutical Industries has named Yitzhak Peterburg as interim CEO. He replaces Erez Vigodman, who stepped down after clinical trial setbacks and the payment of a fine to the U.S. government to settle bribery charges against the company.

Albany Molecular Research Inc. and Bruker Daltonics are joining to develop high-throughput mass spectrometry (MS) for drug discovery at AMRI’s Albany center. AMRI says Bruker’s MALDI PharmaPulse system is the first to allow MS-based assay screening and analysis.

Strides Shasun, previously known as Strides Arcolab, will spin off its active pharmaceutical ingredient (API) business to focus on its core finished drug business. In a statement to the Bombay Stock Exchange, Strides said its API business accounted for 23% of its sales, or $105 million, in the latest fiscal year.

Portola Pharmaceuticals has sold future royalties on its developmental anticoagulation reversal drug andexanet alfa to HealthCare Royalty Partners for $50 million. Portola can get an additional $100 million upon FDA approval of the drug.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.